Gamma-aminobutyric acid type A receptor alpha-3 subunit-containing complex (alpha3-GABAA receptor)

The Gamma-aminobutyric acid type A (GABAA) receptor containing the alpha-3 subunit, typically arranged in an alpha-3-beta-gamma-2 stoichiometry, is a pentameric ligand-gated chloride channel that serves as a primary mediator of fast inhibitory neurotransmission in the mammalian brain and spinal cord (UniProt P34903). These receptors are highly expressed in the cerebral cortex, thalamus, and the dorsal horn of the spinal cord, where they regulate neuronal firing rates and network oscillations (PubMed: 21750159). Pharmacologically, the alpha-3 subunit is a key component of the benzodiazepine binding site, and its activation is specifically associated with anxiolytic, muscle-relaxant, and analgesic effects, distinct from the sedative effects primarily mediated by alpha-1 subunits (PubMed: 22503554). In the context of disease, dysfunction or reduced expression of alpha-3-containing receptors is linked to the pathogenesis of generalized anxiety disorder, schizophrenia, and chronic pain states (PubMed: 21167145). Therapeutic strategies often focus on developing subtype-selective positive allosteric modulators to provide relief from pain and anxiety while avoiding the sedation and motor impairment typical of non-selective GABAergic drugs (StatPearls: NBK513311).

Other names

GABRA3-containing GABAA receptorAlpha-3 subunit-containing GABAA receptoralpha3betaXgamma2 GABAA receptorGABAA receptor alpha-3 subunitGABRA3

Positive allosteric modulation of the GABA-induced chloride current at the benzodiazepine binding site located at the alpha/gamma subunit interface.